Lurasidone HCl
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
Conditions
Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
Trial Timeline
May 1, 2009 → Sep 1, 2009
NCT ID
NCT01074632About Lurasidone HCl
Lurasidone HCl is a phase 1 stage product being developed by Sumitomo Pharma for Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01074632. Target conditions include Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04432688 | Pre-clinical | Completed |
| NCT01143090 | Phase 3 | Completed |
| NCT01143077 | Phase 3 | Completed |
| NCT01074632 | Phase 1 | Completed |
| NCT01082263 | Phase 1 | Completed |
| NCT01074073 | Phase 1 | Completed |
| NCT01082276 | Phase 1 | Completed |
| NCT01082250 | Phase 1 | Completed |
| NCT00549718 | Phase 3 | Completed |
Competing Products
20 competing products in Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder